Sign up
Pharma Capital

Collagen Solutions sees clear path to profitability as commercial development progresses

Collagen Solutions PLC's (LON:COS) Jamal Rushdy and Hilary Spence talk Proactive London's Andrew Scott through the firm's results for the year ended 31 March 2019.

Revenues were up 22% in the year at £4.5mln, while its loss narrowed by just under £500,000 to £1.22mln.

The core business was profitable on an underlying earnings (EBITDA) basis in the final quarter.

Operationally, they landed 29 new customers as it grew its North American business by 72%.


View full COS profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.